The Lubrizol acquires Bavaria Medizin Technologie, an innovative designer, and manufacturer of intravascular and​ nonvascular devices by its German subsidiary Lubrizol Deutschland from its current majority shareholder Custos Vermögensverwaltungs as well as from the minority shareholders. Financial terms were not disclosed. The acquisition of BMT expands Lubrizol’s product design, development, and manufacturing expertise and provides access to proprietary catheter and balloon technologies. “Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space,” Uwe Winzen, General Manager of Lubrizol LifeSciences.